AtriCure

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AtriCure and other ETFs, options, and stocks.

About ATRC

AtriCure, Inc. engages in the development, manufacture, and sale of surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. 

CEO
Michael H. Carrel
CEOMichael H. Carrel
Employees
1,300
Employees1,300
Headquarters
Mason, Ohio
HeadquartersMason, Ohio
Founded
1994
Founded1994
Employees
1,300
Employees1,300

ATRC Key Statistics

Market cap
1.63B
Market cap1.63B
Price-Earnings ratio
-53.87
Price-Earnings ratio-53.87
Dividend yield
Dividend yield
Average volume
766.60K
Average volume766.60K
High today
$34.55
High today$34.55
Low today
$32.72
Low today$32.72
Open price
$33.83
Open price$33.83
Volume
740.31K
Volume740.31K
52 Week high
$43.11
52 Week high$43.11
52 Week low
$28.29
52 Week low$28.29

Stock Snapshot

The current AtriCure(ATRC) stock price is $33.40, with a market capitalization of 1.63B. The stock trades at a price-to-earnings (P/E) ratio of -53.87.

During the trading session on 2025-11-05, AtriCure(ATRC) shares reached a daily high of $34.55 and a low of $32.72. At a current price of $33.40, the stock is +2.1% higher than the low and still -3.3% under the high.

Trading activity shows a volume of 740.31K, compared to an average daily volume of 766.6K.

The stock's 52-week range extends from a low of $28.29 to a high of $43.11.

The stock's 52-week range extends from a low of $28.29 to a high of $43.11.

ATRC News

TipRanks 6d
AtriCure, Inc. Reports Strong Q3 2025 Results

Atricure, Inc. ( (ATRC) ) has released its Q3 earnings. Here is a breakdown of the information Atricure, Inc. presented to its investors. Elevate Your Investin...

Seeking Alpha 6d
AtriCure raises 2025 revenue outlook to $532M–$534M as product launches propel double-digit growth

Earnings Call Insights AtriCure raises 2025 revenue outlook to $532M–$534M as product launches propel double-digit growth Oct. 29, 2025 11:17 PM ET AtriCure, In...

AtriCure raises 2025 revenue outlook to $532M–$534M as product launches propel double-digit growth

Analyst ratings

100%

of 9 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own ATRC. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.